The purpose of this study is to look at the Sodium Magnetic Resonance Imaging (MRI) findings in children with brain tumors and healthy children. An MRI is a machine which takes pictures of the brain. The type of MRI image in this study is a new type that is not yet FDA approved and the study is looking to see if the new type of MRI image is useful in looking at sodium in the brain and brain tumors. Sodium MRI (also known as 23Na-MRI) is a useful non-invasive imaging technique to assess biochemical and physiologic changes in tissues, e.g. integrity of cells and tissue viability. Sodium MRI has been beneficial in the evaluation of several neurological disorders including acute ischemic strokes, multiple sclerosis, amyotrophic lateral sclerosis, migraines, and multiple tumor types, including tumors outside of the central nervous system.

This study is a trial comparing the effects of erenumab to placebo in children ages 6-17 years old with migraine 15 days per month or more. Eligible participants will be given either erenumab or placebo, assigned randomly (like the flip of a coin), followed by an open-label phase in which all participants receive erenumab. Erenumab has been FDA-approved for use in adults to decrease the frequency of migraine. Patients may be eligible to participate if they have had migraine for at least one year, and agree to come to CHOP's main hospital for several study visits. Patients whose headache started suddenly (New Daily Persistent Headache), patients whose headache started after a concussion (Post-Traumatic Headache), and patients with severe depression are not eligible for this study.

This study is a trial comparing the effects of erenumab to placebo in children ages 6-17 years old with migraine less than 15 days per month. Eligible participants will be given either erenumab or placebo, assigned randomly (like the flip of a coin), followed by an open-label phase in which all participants receive erenumab. Erenumab has been FDA-approved for use in adults to decrease the frequency of migraine. Patients may be eligible to participate if they have had migraine for at least one year, and agree to come to CHOP's main hospital for several study visits. Patients whose headache started suddenly (New Daily Persistent Headache), patients whose headache started after a concussion (Post-Traumatic Headache), and patients with severe depression are not eligible for this study.